Fre­quen­cy to hand Nas­daq spot to Ko­r­ro Bio as At­las-found­ed RNA edit­ing start­up nabs $117M

Re­verse merg­ers are in vogue, and Fre­quen­cy Ther­a­peu­tics will join the bo­nan­za, with RNA edit­ing start­up Ko­r­ro Bio ex­pect­ed to take its spot on the Nas­daq in the fourth quar­ter.

The all-stock busi­ness com­bi­na­tion, dis­closed be­fore Fri­day’s open­ing bell, es­sen­tial­ly caps Fre­quen­cy’s nine-year re­gen­er­a­tive med­i­cine jour­ney, based on work out of Bob Langer’s MIT lab. The Boston-area biotech scrapped two hear­ing loss drugs ear­li­er this year af­ter a tri­al flop and sub­se­quent­ly laid off more than half its staff, but still had planned to bring an in­ves­ti­ga­tion­al as­set for mul­ti­ple scle­ro­sis in­to the clin­ic in 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER